Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 6/2007

01.06.2007 | Review Article

Oral Disease-Modifying Treatments for Multiple Sclerosis

The Story So Far

verfasst von: Dr Bernd C. Kieseier, Heinz Wiendl

Erschienen in: CNS Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the CNS. It is the most common cause of neurological disability in young adults and exhibits considerable clinical, radiological and pathological heterogeneity. Increased understanding of the immunopathological processes underlying this disease, advances in biotechnology and the development of powerful magnetic resonance imaging (MRI) technologies, together with improvements in clinical trial design, have led to a variety of valuable therapeutic approaches to MS.
Therapy for MS has changed dramatically over the past decade, yielding significant progress in the treatment of relapsing remitting and secondary progressive forms; however, most of the clinically relevant therapeutic approaches are not yet available as oral formulations. A substantial number of preliminary and pivotal reports have provided promising results for oral therapies, and various phase III clinical trials are currently being initiated or are already underway evaluating the efficacy of a variety of orally administered agents, including cladribine, teriflunomide, laquinimod, fingolimod and fumaric acid. It is hoped that these trials will advance the development of oral therapies for MS.
Literatur
1.
Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49: 281–4PubMedCrossRef
2.
Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003; 23: 133–46PubMedCrossRef
3.
Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 2003; 12: 689–712PubMedCrossRef
4.
Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 2004; 101: 14599–606PubMedCrossRef
5.
Fox RJ, Ransohoff RM. New directions in MS therapeutics: vehicles of hope. Trends Immunol 2004; 25: 632–6PubMedCrossRef
6.
Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16: 183–200PubMedCrossRef
7.
8.
Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–55PubMedCrossRef
9.
Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005; 204: 208–31PubMedCrossRef
10.
Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291–301PubMedCrossRef
11.
Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938–52PubMedCrossRef
12.
13.
Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997; 120: 865–916PubMedCrossRef
14.
15.
Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–21PubMedCrossRef
16.
Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694–706PubMedCrossRef
17.
Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001; 14: 271–8PubMedCrossRef
18.
Zipp F, Krammer PH, Weiler M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 1999; 20: 550–4PubMedCrossRef
19.
Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–8PubMedCrossRef
20.
Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9: 342–8PubMedCrossRef
21.
Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4: 567–75PubMedCrossRef
22.
Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, doubleblind, randomised, placebo-controlled study. Lancet Neurol 2006; 5: 213–20PubMedCrossRef
23.
24.
Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350: 261PubMedCrossRef
25.
Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051–5PubMedCrossRef
26.
Massacesi L, Parigi A, Barilaro A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62: 1843–7PubMedCrossRef
27.
Fernandez O, Guerrero M, Mayorga C, et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J Neurol 2002; 249: 1058–62PubMedCrossRef
28.
Lus G, Romano F, Scuotto A, et al. Azathioprine and interferon beta(la) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004; 51: 15–20PubMedCrossRef
29.
Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-lb. Neurology 2003; 60: 1849–51PubMedCrossRef
30.
Havrdova E, Zivadinov R, Krasensky J, et al. Efficacy results from a randomised, double-blind, placebo-controlled study of intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12Suppl. 1: S11
31.
Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004; (2): CD003208
32.
Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30–40PubMedCrossRef
33.
Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314–7PubMedCrossRef
34.
Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004; 4: 97–107PubMedCrossRef
35.
Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810–21PubMedCrossRef
36.
Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol 1988; 23: 56–63PubMedCrossRef
37.
The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: a randomised, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591–605CrossRef
38.
Zhao GJ, Li DK, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis: the MS study group. J Neuroimaging 1997; 7: 1–7PubMed
39.
Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169–78PubMedCrossRef
40.
Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006; 34: 284–91PubMedCrossRef
41.
Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27: 80–3PubMedCrossRef
42.
Vermersch P, Stojkovic T, de Seze J. Mycophenolate mofetil and neurological diseases. Lupus 2005; 14Suppl. 1: S42–5PubMedCrossRef
43.
Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001; 248: 713–4PubMedCrossRef
44.
Vermersch P, Waucquier N, Michelin E, et al. Combination of IFNbeta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007; 14: 85–9PubMedCrossRef
45.
46.
Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5: 721–7PubMedCrossRef
47.
Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93: 1716–20PubMedCrossRef
48.
Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9–13PubMedCrossRef
49.
Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebocontrolled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35–44PubMedCrossRef
50.
Sipe JC, Romine JS, Koziol JA, et al. Development of cladribine treatment in multiple sclerosis. Mult Scler 1996; 1: 343–7PubMed
51.
Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714–8PubMedCrossRef
52.
Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(l) ‘black hole’ changes in progressive MS. J Neurol Sci 2000; 176: 42–4PubMedCrossRef
53.
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145–55
54.
Brousil JA, Roberts RJ, Schiein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother 2006; 40: 1814–21PubMedCrossRef
55.
56.
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35Suppl. 3: 7–14SCrossRef
57.
Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 2005; 10: 797–816PubMedCrossRef
58.
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5(8): 671–88PubMedCrossRef
59.
Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 2006; 16: 337–41PubMedCrossRef
60.
Kappos L, Barkhof F, Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol 2005; 252Suppl. 2: S46
61.
Hashkes PJ, Laxer RM. Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep 2006; 8: 450–8PubMedCrossRef
62.
Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide: mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950–60PubMedCrossRef
63.
Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2001; 2: 222–30PubMed
64.
Korn T, Toyka K, Hartung HP, et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124: 1791–802PubMedCrossRef
65.
Smolen JS, Emery P, Kalden JR, et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol 2004; 71 Suppl.: 13–20
66.
O’Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894–900PubMedCrossRef
67.
Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163–72PubMedCrossRef
68.
Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new l,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075–88PubMedCrossRef
69.
Runstrom A, Leanderson T, Ohlsson L, et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69–78
70.
Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3–9PubMedCrossRef
71.
Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895–900PubMedCrossRef
72.
Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341–6PubMedCrossRef
73.
Jönsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new l,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075–88PubMedCrossRef
74.
Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987–91PubMedCrossRef
75.
Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1–13PubMedCrossRef
76.
Bielekova B, Lincoln A, McFarland H, et al. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Thl-mediated autoimmune diseases. J Immunol 2000; 164: 1117–24PubMed
77.
Fujimoto T, Sakoda S, Fujimura H, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999; 95: 35–42PubMedCrossRef
78.
Jung S, Huitinga I, Schmidt B, et al. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993; 119: 195–202PubMedCrossRef
79.
Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1: 244–8PubMedCrossRef
80.
Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Thl/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004; 10: 494–8PubMedCrossRef
81.
Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129 (Pt 8): 1940–52PubMedCrossRef
82.
Pershadsingh HA. Peroxisome proliferator-activated receptorgamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004; 13: 215–28PubMedCrossRef
83.
Dello Russo C, Gavrilyuk V, Weinberg G, et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278: 5828–36PubMedCrossRef
84.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89PubMedCrossRef
85.
Storer PD, Xu J, Chavis J, et al. Peroxisome proliferatoractivated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161: 113–22PubMedCrossRef
86.
Diab A, Deng C, Smith JD, et al. Peroxisome proliferatoractivated receptor-gamma agonist 15-deoxy-Delta(12,14) prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508–15PubMed
87.
Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51: 694–702PubMedCrossRef
88.
Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005; 175: 4948–55PubMed
89.
Pershadsingh HA, Heneka MT, Saini R, et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation. Epub 2004 Apr 20
90.
91.
Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991–7PubMed
92.
Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453–7PubMedCrossRef
93.
Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108: 308–19PubMedCrossRef
94.
Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127–59PubMedCrossRef
95.
Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173: 855–65PubMed
96.
Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533–45PubMedCrossRef
97.
Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073–83PubMed
98.
Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70–7PubMedCrossRef
99.
Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 16–24PubMedCrossRef
100.
Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153: 108–21PubMedCrossRef
101.
Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124–40PubMedCrossRef
102.
O’Connor PW, Antel J, Comi G. Oral FTY720 in relapsing MS: results of the dose-blinded, active drug extension phase of a phase II study [abstract]. Neurology 2006; 66: A123CrossRef
103.
Budde K, Schutz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20Suppl. 17: 17–24PubMedCrossRef
104.
Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med 2006; 355: 1088–91PubMedCrossRef
105.
Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an openlabel, baseline-controlled pilot study. Eur J Neurol 2006; 13(6): 604–10PubMedCrossRef
106.
Kappos L, Miller D, MacManus DG, et al. BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12: S85
107.
Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–402PubMedCrossRef
108.
Menge T, Hartung HP, Stuve O. Statins: a cure-all for the brain? Nat Rev Neurosci 2005; 6: 325–31PubMedCrossRef
109.
Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Thl cells through atorvastatin. J Exp Med 2003; 197: 725–33PubMedCrossRef
110.
Paintlia AS, Paintlia MK, Khan M, et al. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb J 2005; 19: 1407–21PubMedCrossRef
111.
Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78–84PubMedCrossRef
112.
Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004; 63: S47–54PubMedCrossRef
113.
Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607–8PubMedCrossRef
114.
Stuve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116: 1037–44PubMedCrossRef
115.
Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52: 421–8PubMedCrossRef
116.
Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998; 95(2): 675–80PubMedCrossRef
117.
Scott GS, Spitsin SV, Kean RB, et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002; 99: 16303–8PubMedCrossRef
118.
119.
Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999; 22: 30–8PubMedCrossRef
120.
Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610–21PubMedCrossRef
121.
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-la for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–23PubMedCrossRef
122.
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899–910PubMedCrossRef
123.
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369–74PubMedCrossRef
124.
Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375–81PubMedCrossRef
125.
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 362–8PubMedCrossRef
126.
Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924–33PubMedCrossRef
127.
128.
129.
130.
131.
Elices MJ. BX-471 Berlex. Curr Opin Investig Drugs 2002; 3: 865–9PubMed
132.
Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006; 67(10): 1880–3PubMedCrossRef
133.
Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107: 140–7PubMedCrossRef
134.
Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931–44PubMedCrossRef
135.
Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297–308PubMedCrossRef
136.
Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215–23PubMedCrossRef
137.
Kieseier BC, Seifert T, Giovannoni G, et al. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999; 53: 20–5PubMedCrossRef
138.
Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744–51PubMedCrossRef
139.
Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2004; 55: 756PubMedCrossRef
140.
Marracci GH, McKeon GP, Marquardt WE, et al. Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res 2004; 78: 362–70PubMedCrossRef
141.
Morini M, Roccatagliata L, Dell’Eva R, et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146–53PubMedCrossRef
142.
Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005; 11: 159–65PubMedCrossRef
Metadaten
Titel
Oral Disease-Modifying Treatments for Multiple Sclerosis
The Story So Far
verfasst von
Dr Bernd C. Kieseier
Heinz Wiendl
Publikationsdatum
01.06.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721060-00005

Weitere Artikel der Ausgabe 6/2007

CNS Drugs 6/2007 Zur Ausgabe

Therapy In Practice

Mood and Anxiety Disorders in Patients with Myasthenia Gravis

Leading Article

Effect of HMG-CoA Reductase Inhibitors on β-Amyloid Peptide Levels

Review Article

Impact of Psychotropic Medications on Simulated Driving

Adis Profile Report

Selegiline Transdermal System in Major Depressive Disorder

Current Opinion

Long-Acting Formulations of Atypical Antipsychotics

Leading Article

Assessing the Role of Drugs in Suicidal Ideation and Suicidality

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise